BRIEF—Immutep raises $53 million

Australian LAG-3 specialist Immutep has raised $53 million to support its late-stage and pipeline development work, including taking eftilagimod alpha into a new Phase III trial in lung cancer.

The firm said it was now “fully funded for its current and expanded clinical program through to Q1 2026 with a pro-forma cash balance of $90.6 million.”

Chairman Russell Howard said the money would help support “late-stage trials in head and neck cancer and metastatic and triple-negative breast cancer, to final data and Phase II read-outs, respectively.”

Mr Howard said the firm was considering conducting a Phase I trial for IMP761, an innovative LAG-3 agonist, for autoimmune diseases.